Linked Life Data

17146284

Source:http://linkedlifedata.com/resource/pubmed/id/17146284

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2006-12-5
pubmed:abstractText
We have established a line of transgenic rats expressing v-erbB, the viral form of epidermal growth factor receptor (EGFR), under transcriptional regulation of the S100beta promoter. Reverse transcriptase-polymerase chain reaction revealed highest transgene expression in the cerebellum followed by the cerebrum, ovary, and testis. Other organs, including the lung, heart, salivary gland, colon, liver, kidney, and spleen, did not show detectable transgene expression. Of 23 homozygous rats that died or were killed because they became moribund between 25 and 91 weeks of age, 15 (65%) showed the presence of brain tumors (mean age, 59 weeks). Of the 10 heterozygous rats killed between 61 and 91 weeks of age, 4 (40%) showed the presence of brain tumors (mean, 77 weeks). With 3 exceptions, all tumors were located within or near the cerebellum (83%). There were 2 major histologic types; one type displayed a solid growth pattern with predominantly perivascular infiltration of adjacent central nervous system tissue and the meninges. Tumors showed histologic features of malignancy with occasional lung metastases. There was a consistent, strong immunoreactivity for S100 protein but no significant expression of glial, neuronal, or meningothelial markers. These tumors were classified as malignant gliomas. A second tumor type was less invasive and characterized by isomorphic cells with round to ovoid nuclei and clear perinuclear halos expressing S100 but no neuronal or glial marker proteins. They were diagnosed as oligodendrogliomas. This is the first transgenic rat model that spontaneously develops brain tumors. Because v-erbB is structurally and functionally similar to the truncated form of EGFR amplified and overexpressed in human glioblastomas, S100beta-v-erbB transgenic rats may serve as a useful animal model for the identification of EGFR-related molecular targets and as a tool for the assessment of novel therapeutic approaches.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0022-3069
pubmed:author
pubmed:issnType
Print
pubmed:volume
65
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1111-7
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:17146284-Animals, pubmed-meshheading:17146284-Animals, Genetically Modified, pubmed-meshheading:17146284-Brain, pubmed-meshheading:17146284-Brain Neoplasms, pubmed-meshheading:17146284-Cell Transformation, Neoplastic, pubmed-meshheading:17146284-Disease Models, Animal, pubmed-meshheading:17146284-Female, pubmed-meshheading:17146284-Genetic Predisposition to Disease, pubmed-meshheading:17146284-Glioma, pubmed-meshheading:17146284-Male, pubmed-meshheading:17146284-Nerve Growth Factors, pubmed-meshheading:17146284-Oligodendroglioma, pubmed-meshheading:17146284-Oncogene Proteins v-erbB, pubmed-meshheading:17146284-Promoter Regions, Genetic, pubmed-meshheading:17146284-Rats, pubmed-meshheading:17146284-Rats, Wistar, pubmed-meshheading:17146284-Recombinant Fusion Proteins, pubmed-meshheading:17146284-S100 Proteins, pubmed-meshheading:17146284-Transfection, pubmed-meshheading:17146284-Transgenes, pubmed-meshheading:17146284-Tumor Markers, Biological
pubmed:year
2006
pubmed:articleTitle
Brain tumors in S100beta-v-erbB transgenic rats.
pubmed:affiliation
International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France. ohgaki@iarc.fr
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural